Sanofi acquires Dynavax Technologies

Sanofi agreed to acquire Dynavax Technologies. Reported deal value: $2.2B. Status: Pending. Sector: Biopharmaceutical. Target headquarters context: Emeryville, California, United States.

This page summarizes publicly available information about the transaction as of 2026-02-13. Figures and status may change as filings and press coverage update.

On February 10, 2026, Sanofi completed its acquisition of U.S.-based Dynavax Technologies Corporation , bringing into its portfolio the marketed adult hepatitis B vaccine HEPLISAV-B and early-stage shingles vaccine candidate Z-1018, along with additional vaccine pipeline assets